NCT04552600View on ClinicalTrials.gov

Study to Evaluate Clinical Efficacy and Safety of Nuvastatic™ - C5OSEW5050ESA in Diabetic Retinopathy.

PHASE1/PHASE2UnknownINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

September 1, 2019

Primary Completion Date

August 31, 2021

Study Completion Date

August 31, 2021

Conditions
Diabetic Retinopathy
Interventions
DRUG

Nuvastatic

Phase 1b Interventional, multi-centered, double-masked, randomized

OTHER

Placebo

Phase 1b Interventional, multi-centered, double-masked, randomized

Trial Locations (1)

411057

RECRUITING

Fifepoint Multispeciality Hospital Pvt. Ltd., Pune

Sponsors
All Listed Sponsors
collaborator

Ministry of Agriculture, Malaysia

UNKNOWN

collaborator

Quest International University, Malaysia.

UNKNOWN

collaborator

Advanced Medical and Dental Institute (AMDI), Universiti Sains Malaysia

UNKNOWN

lead

Natureceuticals Sdn Bhd

INDUSTRY

NCT04552600 - Study to Evaluate Clinical Efficacy and Safety of Nuvastatic™ - C5OSEW5050ESA in Diabetic Retinopathy. | Biotech Hunter | Biotech Hunter